BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

583 related articles for article (PubMed ID: 32436818)

  • 1. The Relevance of Noninvasive Tools To Assess Fibrosis in Non-Alcoholic Fatty Liver Disease.
    Pennisi G; Celsa C; Giammanco A; Spatola F; Petta S
    Curr Pharm Des; 2020; 26(32):3928-3938. PubMed ID: 32436818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease.
    Castera L; Friedrich-Rust M; Loomba R
    Gastroenterology; 2019 Apr; 156(5):1264-1281.e4. PubMed ID: 30660725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.
    Zhou JH; Cai JJ; She ZG; Li HL
    World J Gastroenterol; 2019 Mar; 25(11):1307-1326. PubMed ID: 30918425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
    Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
    APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Fukusato T
    World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016.
    Kaswala DH; Lai M; Afdhal NH
    Dig Dis Sci; 2016 May; 61(5):1356-64. PubMed ID: 27017224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical relevance of liver histopathology and different histological classifications of NASH in adults.
    Nascimbeni F; Ballestri S; Machado MV; Mantovani A; Cortez-Pinto H; Targher G; Lonardo A
    Expert Rev Gastroenterol Hepatol; 2018 Apr; 12(4):351-367. PubMed ID: 29224471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
    Wu J
    Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of noninvasive tests and liver biopsy in the diagnosis of nonalcoholic fatty liver disease.
    Isabela Andronescu C; Roxana Purcarea M; Aurel Babes P
    J Med Life; 2018; 11(3):243-246. PubMed ID: 30364513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Concepts.
    Papatheodoridi M; Cholongitas E
    Curr Pharm Des; 2018; 24(38):4574-4586. PubMed ID: 30652642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis of nonalcoholic fatty liver disease (NAFLD).
    Yki-Järvinen H
    Duodecim; 2016; 132(22):2099-106. PubMed ID: 29190058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum coding and non-coding RNAs as biomarkers of NAFLD and fibrosis severity.
    Di Mauro S; Scamporrino A; Petta S; Urbano F; Filippello A; Ragusa M; Di Martino MT; Scionti F; Grimaudo S; Pipitone RM; Privitera G; Di Pino A; Scicali R; Valenti L; Dongiovanni P; Fracanzani A; Rabuazzo AM; Craxì A; Purrello M; Purrello F; Piro S
    Liver Int; 2019 Sep; 39(9):1742-1754. PubMed ID: 31169972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography.
    Tsai E; Lee TP
    Clin Liver Dis; 2018 Feb; 22(1):73-92. PubMed ID: 29128062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Research progress of omics biomarkers for nonalcoholic fatty liver disease].
    Wang L; Liu XE; Zhuang H
    Zhonghua Gan Zang Bing Za Zhi; 2021 Jun; 29(6):604-608. PubMed ID: 34225440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to Date.
    Albhaisi S; Sanyal AJ
    Pharmaceut Med; 2019 Dec; 33(6):451-463. PubMed ID: 31933238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Natural Course of Non-Alcoholic Fatty Liver Disease.
    Calzadilla Bertot L; Adams LA
    Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27213358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SWOT analysis of noninvasive tests for diagnosing NAFLD with severe fibrosis: an expert review by the JANIT Forum.
    Kamada Y; Nakamura T; Isobe S; Hosono K; Suama Y; Ohtakaki Y; Nauchi A; Yasuda N; Mitsuta S; Miura K; Yamamoto T; Hosono T; Yoshida A; Kawanishi I; Fukushima H; Kinoshita M; Umeda A; Kinoshita Y; Fukami K; Miyawaki T; Fujii H; Yoshida Y; Kawanaka M; Hyogo H; Morishita A; Hayashi H; Tobita H; Tomita K; Ikegami T; Takahashi H; Yoneda M; Jun DW; Sumida Y; Okanoue T; Nakajima A;
    J Gastroenterol; 2023 Feb; 58(2):79-97. PubMed ID: 36469127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathology of non-alcoholic fatty liver disease.
    Cataldo I; Sarcognato S; Sacchi D; Cacciatore M; Baciorri F; Mangia A; Cazzagon N; Guido M
    Pathologica; 2021 Jun; 113(3):194-202. PubMed ID: 34294937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Noninvasive Tests for Differentiating NASH From NAFL and Diagnosing Advanced Fibrosis Among Patients With NAFLD.
    Balakrishnan M; Loomba R
    J Clin Gastroenterol; 2020 Feb; 54(2):107-113. PubMed ID: 31789757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver fibrosis markers of nonalcoholic steatohepatitis.
    Enomoto H; Bando Y; Nakamura H; Nishiguchi S; Koga M
    World J Gastroenterol; 2015 Jun; 21(24):7427-35. PubMed ID: 26139988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.